


## Cabotegravir-d<sub>3</sub> sodium

<b>Cat. No.:</b>	HY-15592AS
<b>Molecular Formula:</b>	C <sub>19</sub> H <sub>13</sub> D <sub>3</sub> F <sub>2</sub> N <sub>3</sub> NaO <sub>5</sub>
<b>Molecular Weight:</b>	430.35
<b>Target:</b>	HIV Integrase; Isotope-Labeled Compounds
<b>Pathway:</b>	Metabolic Enzyme/Protease; Others
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Cabotegravir-d <sub>3</sub> (sodium) is the deuterium labeled Cabotegravir sodium. Cabotegravir sodium is a highly potent HIV integrase inhibitor with an IC <sub>50</sub> value of 2.5 nM for HIVADA. Cabotegravir sodium is primarily metabolized by uridine diphosphate glucuronosyltr
<b>In Vitro</b>	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother*. 2019 Feb;53(2):211-216.
- [2]. Zhou T, et al. Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles. *Biomaterials*. 2018 Jan;151:53-65.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA